先進的ながん免疫療法を、
日本の専門クリニックで、
あなたのために調整します

Japan regulates advanced cell-based medicine through a dedicated legal framework, overseen by the Ministry of Health, Labour and Welfare and the PMDA. Pathways such as Advanced Medical Care (Senshin Iryo) and the Act on the Safety of Regenerative Medicine let licensed clinics offer certain therapies outside a clinical trial, under defined safeguards. That is why some approaches are routinely available in Japan while they are still trial-only elsewhere. It does not mean they are right for everyone — that is a separate question. Through our medical concierge services, we review health records and diagnostic history provided by patients to identify the most relevant clinical paths. We help connect patients with authorized specialized clinics in Japan best equipped to evaluate each patient's situation and provide the appropriate treatment protocols for their specific case.

Most Japanese specialized clinics do not accept international patients directly. Japan Medical Assist bridges this gap by acting as your official administrative coordinator. Here is how we help you successfully secure treatment:

• Overcoming language barriers: Japanese medical facilities communicate exclusively in Japanese. We handle all official correspondence and provide professional document translation services for your records.
• Complex record preparation: clinics require strict, specific health record formats and preliminary screening protocols. We organize your medical history to meet precise Japanese standards.
• Multi-clinic network: treatment protocols vary widely, and clinics frequently decline cases. We leverage established relationships with multiple facilities to find the best match for your specific diagnosis.
• Expedited registration: Japanese oncology centers can be overwhelmed with inquiries. We present your case as a "ready-to-review" medical case, bypassing administrative delays to fast-track your intake.
• On-site interpretation support: to ensure safety and clear communication during your medical appointments, we provide in-person interpretation services at the clinic when necessary.

We do not choose a treatment or decide whether you are medically suitable. Those decisions belong to the independent doctors reviewing your case.

That depends on your diagnosis, previous treatment, current health and the services available at the reviewing institution. A discussion may cover established cancer care, a clinical trial, or a private-pay approach that is non-standard or investigational. Examples of approaches you may hear about include:

• Dendritic-cell vaccines — dendritic cells are prepared from the patient's blood and exposed to selected tumour antigens or tumour material. The intended mechanism is to support antigen presentation to T cells.
• Autologous tumour vaccines — suitable tumour material from the same patient is processed into a vaccine preparation intended to expose the immune system to tumour-associated material.
• Immune-cell approaches — selected immune cells, such as natural killer (NK) cells or other lymphocyte populations, may be collected, prepared or expanded outside the body and then administered back to the patient.
• Tumour-directed or supportive procedures — a doctor may also discuss local or supportive procedures, including heat-based approaches, where clinically relevant.

Mention in this FAQ does not mean that an approach is approved for your cancer, supported by strong evidence, available at every institution or suitable for you. Do not stop or delay established care while exploring an additional option.

No. They use different materials and biological mechanisms:

• Dendritic-cell vaccines use antigen-presenting cells prepared from the patient's blood. They are intended to help T cells recognise selected tumour-associated antigens.
• Autologous tumour vaccines are made using suitable tumour material taken from the same patient. They are not interchangeable with dendritic-cell vaccines.
• NK-cell approaches involve natural killer cells, which are part of the innate immune system and can respond to certain abnormal cells without being directed to one specific antigen.
• NKT-cell-directed approaches involve a distinct immune-cell population with features of both innate and adaptive immunity. The collection, preparation and administration process varies by protocol.

These mechanism descriptions do not establish clinical benefit. Ask the doctor what exact preparation is being proposed and what evidence supports its use in your situation.

Most likely. The reviewing team might request a formalin-fixed paraffin-embedded (FFPE) tissue block, unstained slides, stained pathology slides, a pathology report, or information about fresh or frozen tissue. These materials can be used for pathology review, immunohistochemistry, antigen testing or, in some protocols, preparation of a patient-specific product. Unstained slides can be useful for testing but may not contain enough material to replace a tissue block when manufacturing requires a larger quantity. Please discuss with your current pathology department possible tissue release and confirm what is available before sending anything.

Do not send tissue until the clinic confirms in writing the exact material, amount, age limits, labelling, shipping conditions, and whether the material will be returned. Your local pathology department must also retain enough material for diagnosis and future standard-care testing.

Tell us what the pathology department can provide. The clinic may be able to assess slides, digital pathology images, a pathology report or existing molecular results, but these may not substitute for the material required by a particular test or manufacturing process. Only the receiving clinic or laboratory teams can confirm whether the available specimen is sufficient.

Apheresis is more involved than a routine blood draw. Blood passes through a machine that separates and collects selected components, while the remaining blood is returned to the patient. It may be used to collect cells before laboratory preparation of a cell-based product. The length of the procedure, type of venous access, amount collected and whether one collection can support more than one preparation depend on the protocol and the patient's condition.

Sometimes a clinic may work with an approved collection facility, but this must be confirmed before making arrangements. Cell collection and transport can involve strict requirements for eligibility, collection equipment, labelling, chain of identity, temperature control, timing and cross-border shipment. A local blood draw should not be assumed to be interchangeable with the collection required by the receiving clinic.

If a clinic accepts a patient, online consultation is required to discuss case details and potential treatment pathways. Being offered a video consultation is a good sign that the clinic is considering the case. If a consultation is offered, we can coordinate the time zone, connection details and interpretation arrangements.

Send the most recent and relevant information you already have:

• A medical summary and timeline of the diagnosis and treatment so far.
• Pathology reports, molecular or genomic test results, and information about stored tumour material.
• CT, MRI or PET-CT images in DICOM format, together with the radiology reports.
• Recent blood tests and other relevant examination results.
• A current medicine list, including doses, and the schedule of any ongoing treatment.
• A note about recent changes, such as new symptoms, hospital admission or a planned procedure.

If something is missing, send what you have and identify the gap. The reviewing institution will decide what is required before it can give an opinion or confirm a visit.

Read the educational material supplied for the consultation and write down your questions. Have your current medicine and treatment schedule nearby. Decide what you most need to understand, and tell the doctor about any recent change in your condition. An interpreted appointment can take longer than a conversation in one language, so it helps to put your most important questions first.

Ask for the exact name and purpose of each proposed component, its regulatory status, the quality of evidence for your situation, known and uncertain risks, alternatives, possible interactions with current care, specimen or blood-collection requirements, monitoring, travel schedule and full cost. Ask who will manage complications in Japan and after you return home. If an answer is unclear, ask the doctor to explain it in simpler terms.

Upload them to your secure patient workspace. Access is limited to authorised coordinators working on your case and the medical teams asked to review it. We can also help request records from your current care team when you authorise us to do so.

No. Send the original records first. We will identify which documents the reviewing institution needs translated so you do not spend time or money translating material that is not required.

We check that the administrative file is organised and identify obvious gaps. An independent medical institution then decides whether it will review the case, which doctor will review it and whether more information is needed. Japan Medical Assist does not perform the medical assessment.

Timing varies with record completeness, translation needs, medical complexity and the institution's schedule. There may be separate stages for administrative preparation, medical screening, consultation and a written proposal. We will share confirmed updates rather than promise a date before the reviewing institution responds.

We provide administrative coordination: organising and translating records, communicating with medical institutions, arranging consultations and interpreters, and helping with confirmed travel and appointment logistics. We do not provide clinical care.

Only licensed healthcare professionals responsible for your care. Diagnoses, eligibility decisions, treatment recommendations, consent and follow-up instructions come from them, not from Japan Medical Assist.

Wait until the medical institution has confirmed the required appointments and you have reviewed the fees, entry requirements and cancellation terms. Laboratory preparation, test results or changes in your condition can affect dates. Flexible bookings may reduce the impact of a schedule change.

There is no standard length. A visit may range from a short consultation or procedure to several weeks. A cell-based process may include screening, cell collection, laboratory preparation and later administrations, so it may require one longer stay or more than one trip. Use only the written schedule confirmed for your case before arranging travel.

Your case documents preparation and clinic matching are free and carry no obligation. Treatment costs come after the clinic has reviewed your file, because they depend on what is actually being proposed — anyone quoting a treatment price before reading your records is guessing. You will get a full breakdown before deciding anything. Online consultation with a doctor is billed separately by the clinic, and you will see that cost before booking. We will credit the consultation cost toward the treatment cost if you go ahead. While treatments costs range from $50,000 to $200,000, the exact amount will depend on your specific case and the proposed treatment plan.

Usually not. These are private treatments at independent clinics and most policies do not reimburse them. Check with your insurer directly. Depending on your local taxation rules, the costs may qualify for a medical expense tax deduction.

Licensed clinicians assess response using the information appropriate to the disease and treatment, which may include symptoms, examination, imaging and laboratory results. A change in a tumour marker or immune marker alone may not show whether a tumour has responded or whether a person will live longer. Japan Medical Assist can transfer records and arrange follow-up communication, but does not interpret results.

Use the secure patient workspace or contact your coordinator. We can help transfer new records, request the treating institution's follow-up instructions, arrange interpretation and coordinate a later consultation or visit. Medical concerns should be directed to the clinicians responsible for your care, and urgent symptoms should be handled locally without waiting for a coordinator response.